Ultrasmall silver nanoparticles were prepared by reduction with NaBH4 and surface-terminated with glutathione (GSH). The particles had a solid core diameter of 2 nm as shown by transmission electron microscopy (TEM) and small-angle X-ray scattering (SAXS). NMR-DOSY gave a hydrodynamic diameter of 2 to 2.8 nm. X-ray photoelectron spectroscopy (XPS) showed that silver is bound to the thiol group of the central cysteine in glutathione under partial oxidation to silver­(+I). In turn, the thiol group is deprotonated to thiolate. X-ray powder diffraction (XRD) together with Rietveld refinement confirmed a twinned (polycrystalline) fcc structure of ultrasmall silver nanoparticles with a lattice compression of about 0.9% compared to bulk silver metal. By NMR spectroscopy, the interaction between the glutathione ligand and the silver surface was analyzed, also with 13C-labeled glutathione. The adsorbed glutathione is fully intact and binds to the silver surface via cysteine. In situ 1H NMR spectroscopy up to 85 °C in dispersion showed that the glutathione ligand did not detach from the surface of the silver nanoparticle, i.e. the silver–sulfur bond is remarkably strong. The ultrasmall nanoparticles had a higher cytotoxicity than bigger particles in in vitro cell culture with HeLa cells with a cytotoxic concentration of about 1 μg mL–1 after 24 h incubation. The overall stoichiometry of the nanoparticles was about Ag∼250GSH∼155.

Ultrasmall nanoparticles of platinum group metal oxides (core diameter of about 1.8 nm) were prepared by alkaline hydrolysis of metal precursors in the presence of NaBH4 and by colloidal stabilization with tripeptide glutathione. We obtained water-dispersed nanoparticles of Rh2O3, PdO, RuO2, IrO2, Os/OsO2, and Pt/PtO. Their size was probed using high-resolution transmission electron microscopy, differential centrifugal sedimentation, small-angle X-ray scattering, and diffusion-ordered 1H NMR spectroscopy (1H DOSY). Their oxidation state was clearly determined using X-ray photoelectron spectroscopy, X-ray powder diffraction, and electron diffraction. The chemical composition of the nanoparticles, that is, the ratio of the metal oxide core and glutathione capping agent, was quantitatively determined by a combination of these methods.

Two ways to deliver ultrasmall gold nanoparticles and gold-bovine serum albumin (BSA) nanoclusters to the colon were developed. First, oral administration is possible by incorporation into gelatin capsules that were coated with an enteric polymer. These permit the transfer across the stomach whose acidic environment damages many drugs. The enteric coating dissolves due to the neutral pH of the colon and releases the capsule’s cargo. Second, rectal administration is possible by incorporation into hard-fat suppositories that melt in the colon and then release the nanocarriers. The feasibility of the two concepts was demonstrated by in-vitro release studies and cell culture studies that showed the easy redispersibility after dissolution of the respective transport system. This clears a pathway for therapeutic applications of drug-loaded nanoparticles to address colon diseases, such as chronic inflammation and cancer.